Diagnosis and treatment of pulmonary artery hypertension

Current Opinion in Pediatrics

Volumn 8, Issue 5, 1996, Pages 512-519

  Barst, Robyn J ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIGITALIS; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; CHILD; EISENMENGER COMPLEX; EXERCISE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LUNG TRANSPLANTATION; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG HEMODYNAMICS; NEWBORN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0029857433     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199610000-00016     Document Type: Review

References (36)

1. Heath D, Edwards JE: The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958, 18:533-547.
2. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM: Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978, 58:1107-1122.
3. Wood P: The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ 1958, 2:701-709.
4. Haworth SG: Pulmonary hypertension in childhood. Eur Respir J 1993, 6:1037-1043.
5. Wagenvoort CA, Wagenvoort N: Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970, 42:1163-1184.
6. Rubin LJ: Primary pulmonary hypertension. Chest 1993, 104:236-250.
7. Wagenvoort CA, Wagenvoort N: Pathology of Pulmonary Hypertension. New York: Wiley & Sons; 1977.
8. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70-75.
9. Stewart DJ, Levy RD, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991, 114:467-469.
10. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib A, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:173-176.
11. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW: Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987, 107:216-223.
12. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Kean JF, O'Fallon WM, Pieroni DR, Wolfe RR, Weidman WH: Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 1993, 87:38-51.
13. Yamaki S, Mohri H, Haneda K, Endo M, Akimoto H: Indications for surgery based on lung biopsy in cases of ventricular septal defects and/or patent ductus with severe pulmonary hypertension. Chest 1989, 96:31-39.
14. Roberts JD Jr, Lan P, Bigatello LM, Vlahakes GJ, Zapol WM: Inhaled nitric oxide in congenital heart disease. Circulation 1993, 87:447-453.
15. Miller OI, Celemajer DS, Deanfield JE, Marae DJ: Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994, 108:487-494.
16. Atz AM, Adatia I, Jonas RA, Wessel DL: Inhaled nitric oxide in children with pulmonary hypertension and congenital mitral stenosis. Am J Cardiol 1996, 77:316-319. A study of 15 patients with congenital mitral stenosis and pulmonary hypertension evaluated with inhaled nitric oxide to assess the extent of reversible pulmonary hypertension and explore its therapeutic uses. The study demonstrates selective pulmonary vasodilation with nitric oxide and its chronic use after intervention.
17. Berner M, Beghetti M, SpahrSchopfer I, Oberhansli I, Friedli B: Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996, 77:532-535. The usefulness of nitric oxide induced pulmonary vasodilatation is again demonstrated in a study of 13 children with pulmonary hypertension and elevated pulmonary vascular resistance. The efficacy of inhaled nitric oxide to assess surgical operabillty is discussed.
18. Bush A, Busst C, Knight WB, Shinebourne EA: Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy. Am Rev Respir Dis 1987, 136:767-769.
19. Beghetti M, Habre W, Friedli B, Berner M: Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995, 73:65-68.
20. Cremona G, Higenbottam T: Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 1995, 75:67A-71A. A review of therapy with continuous intravenous prostacyclin in the treatment of primary pulmonary hypertension is presented. The paper summarizes previous studies as well as clinical uses of prostacyclin, acute effects, and long-term effects. Side effects and complications are also discussed.
21. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ: Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993, 99:2128-2138.
22. Hopkins RA, Bull C, Haworth SG, DeLeval MR, Stark J: Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 1991, 5:628-634.
23. Barst RJ: Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986, 98:497-503.
24. Barst RJ: Primary pulmonary hypertension in children. In Primary Pulmonary Hypertension (Lung Biology in Health and Disease). Edited by Rubin LJ, Rich S. New York: Marcel Dekker; 1996, in press. Evaluation and therapy of children with primary pulmonary hypertension is presented in depth in this chapter.
25. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA: Effect of long-term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986, 55:385-390.
26. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
27. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984, 70:580-587.
28. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-301. A multicenter study evaluating chronic intravenous prostacyclin versus standard therapy for the treatment of primary pulmonary hypertension. This randomized study is the first study to result in a Food and Drug Administration-approved drug for the therapy of PPH. In addition to improved exercise capacity, improved hemodynamics, and improved quality of life, survival was also improved during this 12-week randomized study.
29. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Feduloo PF, Moser KM: Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996, 109:1545-1549. This paper reports the first use of chronic inhaled nitric oxide to treat patients with primary pulmonary hypertension. Despite this not being a randomized study and with only limited follow-up data presented, the authors discuss the potential advantages for this new therapeutic modality.
30. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azaian R, Herve P, Raffestin B, Simonneau G: Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 151:384-389.
31. Rozkovec A, Montanes P, Oakley C: Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 1986, 55:449-458.
32. Young D, Mark H: Fate of the patient with Eisenmenger's syndrome. Am J Cardiol 1971, 65:655-669.
33. Hausknecht MJ, Sims RE, Nihill MR, Cashion WR: Successful palliation of primary pulmonary hypertension by atrial septostomy. Am J Cardiol 1990, 65:1045-1046.
34. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ: Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension. Circulation 1995, 91:2028-2035.
35. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M, Sundaresan S, Cox JL, Patterson GA: Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients. Circulation 1995, 92:2252-2258. The study presents the most recent and best results published to date for lung transplantation with patients who have severe pulmonary hypertension. One-year, 2-year, and 3-year survival rates for 34 patients undergoing transplantation were 78%, 66%, and 61%, respectively. In the 24 patients with primary pulmonary hypertension, the 1-, 2-, and 3-year survival rates were 87%, 76%, and 68%, respectively.
36. Pepke-Zaba J, Higenbottam T, Dinh-Xuan AT, Stone D, Wallwork J: Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991, 338:1173-1174.